Wednesday, July 8, 2026

Patent intelligence · US

US 8110209

Intracutaneous injection

granted A61KA61K38/26A61K38/27A61K47/14
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 6
Applicant portfolio 24
Patent details — US 8110209
Jurisdiction
US
Status
granted
Grant date
Feb 7, 2012
Expiration
Feb 2, 2032
Claims
19
CPC classes
A61K, A61K38/26, A61K38/27, A61K47/14
View on Google Patents ↗

Quick answer

US 8110209 (Intracutaneous injection) is held by XERIS PHARMACEUTICALS, INC.. Status: granted. Granted Feb 7, 2012. Expires Feb 2, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61K, A61K38/26, A61K38/27, A61K47/14, A61K47/22, A61K9/0014

More from XERIS PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12377096

    Methods of treating disease with levoketoconazole

    XERIS PHARMACEUTICALS, INC. · Expires Jul 31, 2045

    granted
  2. US 11964003

    Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    XERIS PHARMACEUTICALS, INC. · Expires Apr 18, 2044

    granted
  3. US 11957736

    Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    XERIS PHARMACEUTICALS, INC. · Expires Apr 11, 2044

    granted
  4. US 11833157

    Precipitation resistant small molecule drug formulations

    XERIS PHARMACEUTICALS, INC. · Expires Nov 30, 2043

    granted
  5. US 11590205

    Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

    XERIS PHARMACEUTICALS, INC. · Expires Feb 23, 2043

    granted
  6. US 11576951

    Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    XERIS PHARMACEUTICALS, INC. · Expires Feb 9, 2043

    granted
  7. US 11446310

    Stable formulations for parenteral injection of small molecule drugs

    XERIS PHARMACEUTICALS, INC. · Expires Sep 15, 2042

    granted
  8. US 11129940

    Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes

    XERIS PHARMACEUTICALS, INC. · Expires Sep 23, 2041

    granted

Frequently asked questions

What is US patent 8110209?

US 8110209 (Intracutaneous injection) is held by XERIS PHARMACEUTICALS, INC.. Status: granted. Granted Feb 7, 2012. Expires Feb 2, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8110209?

XERIS PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.

When does US 8110209 expire?

Our index shows an expiration date of Feb 2, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.